Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CHRO NASDAQ:CLSD NASDAQ:MRSN NASDAQ:SNYR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHROChromocell Therapeutics$1.34+6.3%$6.85$4.50▼$38.00$8.69M3.6347,337 shs194,032 shsCLSDClearside Biomedical$0.38-7.8%$0.72$0.29▼$1.65$32.37M2.0913.04 million shs814,430 shsMRSNMersana Therapeutics$6.60-3.6%$8.50$6.37▼$70.75$34.15M0.83130,548 shs110,562 shsSNYRSynergy CHC$3.36-2.9%$2.83$0.36▼$10.00$31.81MN/A54,733 shs29,375 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHROChromocell Therapeutics0.00%0.00%0.00%-89.37%-87.48%CLSDClearside Biomedical-7.80%-22.75%-52.34%-55.84%-66.31%MRSNMersana Therapeutics-3.65%-18.04%-5.61%-33.62%-86.80%SNYRSynergy CHC-2.89%-11.35%+3.70%+57.75%+3,260.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHROChromocell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACLSDClearside Biomedical3.0171 of 5 stars4.15.00.00.02.80.00.0MRSNMersana Therapeutics4.0345 of 5 stars3.44.00.04.11.62.50.0SNYRSynergy CHC3.8798 of 5 stars3.80.00.00.03.33.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHROChromocell Therapeutics 0.00N/AN/AN/ACLSDClearside Biomedical 2.17Hold$4.20993.47% UpsideMRSNMersana Therapeutics 2.83Moderate Buy$130.001,869.70% UpsideSNYRSynergy CHC 3.50Strong Buy$10.00197.62% UpsideCurrent Analyst Ratings BreakdownLatest CHRO, CLSD, SNYR, and MRSN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/18/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$5.007/18/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/18/2025CLSDClearside BiomedicalStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$2.007/17/2025CLSDClearside BiomedicalJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/17/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$3.006/3/2025MRSNMersana TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/23/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.005/16/2025CLSDClearside BiomedicalJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.005/16/2025MRSNMersana TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$225.00 ➝ $250.005/16/2025MRSNMersana TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$125.00 ➝ $125.005/15/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHROChromocell TherapeuticsN/AN/AN/AN/A($1.65) per shareN/ACLSDClearside Biomedical$1.66M17.98N/AN/A($0.51) per share-0.75MRSNMersana Therapeutics$40.50M0.81N/AN/A($1.92) per share-3.44SNYRSynergy CHC$34.83M0.89$0.26 per share13.01($1.91) per share-1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHROChromocell Therapeutics-$7.38M-$1.24N/A∞N/AN/AN/A-453.90%N/ACLSDClearside Biomedical-$34.35M-$0.41N/AN/AN/A-818.57%N/A-114.23%8/11/2025 (Estimated)MRSNMersana Therapeutics-$69.19M-$14.75N/AN/AN/A-217.63%-990.16%-48.87%8/12/2025 (Estimated)SNYRSynergy CHC$2.12MN/A0.005.69N/AN/A-8.48%12.75%N/ALatest CHRO, CLSD, SNYR, and MRSN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MRSNMersana Therapeutics-$0.18N/AN/AN/A$6.06 millionN/A8/11/2025Q2 2025CLSDClearside Biomedical-$0.12N/AN/AN/A$0.50 millionN/A5/15/2025Q1 2025MRSNMersana Therapeutics-$5.25-$4.75+$0.50-$0.19$6.05 million$2.75 million5/15/2025Q1 2025SNYRSynergy CHC$0.07$0.10+$0.03$0.10$9.03 million$8.17 million5/14/2025Q1 2025CLSDClearside Biomedical-$0.12-$0.11+$0.01-$0.11$0.20 million$2.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHROChromocell TherapeuticsN/AN/AN/AN/AN/ACLSDClearside BiomedicalN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/ASNYRSynergy CHCN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHROChromocell TherapeuticsN/A0.600.60CLSDClearside BiomedicalN/A3.193.19MRSNMersana TherapeuticsN/A1.831.83SNYRSynergy CHCN/A1.911.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHROChromocell Therapeutics77.96%CLSDClearside Biomedical18.75%MRSNMersana Therapeutics93.92%SNYRSynergy CHCN/AInsider OwnershipCompanyInsider OwnershipCHROChromocell Therapeutics16.40%CLSDClearside Biomedical6.20%MRSNMersana Therapeutics13.00%SNYRSynergy CHC56.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHROChromocell Therapeutics46.49 million5.04 millionN/ACLSDClearside Biomedical3077.71 million72.89 millionOptionableMRSNMersana Therapeutics1504.99 million4.34 millionOptionableSNYRSynergy CHC409.19 million3.99 millionN/ACHRO, CLSD, SNYR, and MRSN HeadlinesRecent News About These CompaniesInsider Buying: Synergy CHC Corp. (NASDAQ:SNYR) CEO Purchases 3,750 Shares of StockAugust 1 at 6:41 AM | insidertrades.comSynergy CHC Corp. Announces Second Quarter 2025 Earnings and Conference Call InformationJuly 31 at 12:47 AM | manilatimes.netMSynergy CHC Corp. Stock (SNYR) Opinions on Retail Distribution ExpansionJuly 31 at 1:12 PM | quiverquant.comQReviewing Synergy CHC (NASDAQ:SNYR) & Swatch Group (OTCMKTS:SWGAY)July 29, 2025 | americanbankingnews.comSynergy CHC Expands Retail Presence in North AmericaJune 30, 2025 | tipranks.comSynergy CHC Corp. (SNYR) Stock Price Today - WSJJune 24, 2025 | wsj.comSynergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® to UAE & Turkey — Ignites Global Growth and New Revenue StreamsJune 18, 2025 | finance.yahoo.comSynergy CHC Corp. Expands International Licensing Deal with Gravity Pharma to Include Turkey, Securing $2 Million in RevenueJune 18, 2025 | quiverquant.comQHere is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)June 18, 2025 | finance.yahoo.comHere is What You Need to Know Before Investing in Synergy CHC Corp. (SNYR)June 16, 2025 | insidermonkey.comSynergy CHC Corp. (Uplisting) (NASDAQ:SNYR) CEO Jack Ross Buys 9,400 SharesJune 12, 2025 | insidertrades.comNew to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink’s Global ExpansionJune 11, 2025 | freep.comFNew to The Street TV Spotlights Synergy CHC (NASDAQ:SNYR) as Former Coca-Cola Executive Joins to Drive FOCUSfactor(R) Energy Drink's Global ExpansionJune 10, 2025 | guardonline.comGSynergy CHC Corp. Appoints Damian Marano as Vice President of Beverage to Accelerate Functional Beverage ExpansionJune 10, 2025 | quiverquant.comQSynergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global ExpansionJune 10, 2025 | globenewswire.comSynergy CHC secures $20 million loan for growth and debt repaymentJune 5, 2025 | investing.comSynergy CHC Secures $20 Million Loan AgreementJune 4, 2025 | msn.comSynergy CHC Announces New $20 Million Long-Term Credit FacilityJune 4, 2025 | globenewswire.comSNYR Synergy CHC Corp.May 30, 2025 | seekingalpha.comSynergy CHC Announces Appointment of Erik Shields as Vice President of BeverageMay 29, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCHRO, CLSD, SNYR, and MRSN Company DescriptionsChromocell Therapeutics NYSE:CHRO$1.34 +0.08 (+6.35%) Closing price 07/1/2025Extended Trading$1.34 0.00 (0.00%) As of 07/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.Clearside Biomedical NASDAQ:CLSD$0.38 -0.03 (-7.80%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.39 +0.01 (+2.58%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Mersana Therapeutics NASDAQ:MRSN$6.60 -0.25 (-3.65%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.60 0.00 (0.00%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Synergy CHC NASDAQ:SNYR$3.36 -0.10 (-2.89%) As of 08/1/2025 04:00 PM EasternSynergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
